PHF filed the DMF for Solifenacin succinate in the USA (DMF No. 025488).
Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion. Solifenacin succinate is indicated for the treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and
urinary frequency.